HTG Molecular Diagnostics (HTGM) Posts Earnings Results, Beats Estimates By $0.15 EPS

HTG Molecular Diagnostics (NASDAQ:HTGM) released its quarterly earnings results on Thursday. The medical research company reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.15, Fidelity Earnings reports. The company had revenue of $7.90 million during the quarter, compared to analysts’ expectations of $7.05 million.

HTGM stock opened at $4.47 on Friday. HTG Molecular Diagnostics has a 12-month low of $1.59 and a 12-month high of $13.25.

How to Become a New Pot Stock Millionaire

Several research analysts recently commented on HTGM shares. HC Wainwright set a $6.00 price target on HTG Molecular Diagnostics and gave the stock a “buy” rating in a research report on Wednesday, December 27th. Canaccord Genuity boosted their target price on HTG Molecular Diagnostics to $5.00 in a research report on Friday, January 5th. Finally, Zacks Investment Research lowered HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $6.56.

A hedge fund recently raised its stake in HTG Molecular Diagnostics stock. Vanguard Group Inc. raised its holdings in shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 38.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 135,234 shares of the medical research company’s stock after buying an additional 37,841 shares during the period. Vanguard Group Inc. owned about 1.42% of HTG Molecular Diagnostics worth $359,000 at the end of the most recent reporting period. Institutional investors own 7.91% of the company’s stock.

TRADEMARK VIOLATION WARNING: “HTG Molecular Diagnostics (HTGM) Posts Earnings Results, Beats Estimates By $0.15 EPS” was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/3296578/htg-molecular-diagnostics-htgm-posts-earnings-results-beats-estimates-by-0-15-eps.html.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Earnings History for HTG Molecular Diagnostics (NASDAQ:HTGM)

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Somewhat Positive Press Coverage Somewhat Unlikely to Affect GoPro  Stock Price
Somewhat Positive Press Coverage Somewhat Unlikely to Affect GoPro Stock Price
BlackRock Enhanced Capital And Income Fund  Earning Favorable Media Coverage, Study Finds
BlackRock Enhanced Capital And Income Fund Earning Favorable Media Coverage, Study Finds
Voya Prime Rate Trust  Earns Media Impact Score of 0.21
Voya Prime Rate Trust Earns Media Impact Score of 0.21
Female Health  Upgraded to “Hold” by Zacks Investment Research
Female Health Upgraded to “Hold” by Zacks Investment Research
TrustCo Bank  Lowered to Hold at BidaskClub
TrustCo Bank Lowered to Hold at BidaskClub
Bitcoin Trading 9.9% Higher  This Week
Bitcoin Trading 9.9% Higher This Week


© 2006-2018 Ticker Report. Google+.